Virally
vectored vaccines expressing novel antigens will be provided as TNA activities.
Not exact matches
The laboratory has also all of the technologies required to produce recombinant bacteria
expressing vaccine antigens to be used as non-pathogenic
vaccine vectors.
Firstly, it will develop optimised viral
vectors suitable for
expressing antigens from a range of different diseases, to create novel
vaccines.
Moreover, UNISI produces recombinant bacteria
expressing vaccine antigens to be used as non-pathogenic
vaccine vectors.
MVDVax is a measles based Dengue
vaccine where dengue antigens are
expressed in a measles
vector.
2009 — Developed an MVA HIV
Vaccine Candidate — MHRP and NIAID researchers developed a new HIV vaccine, specific to the strain of HIV circulating in Southeast Asia that is expressed in a modified smallpox virus vector
Vaccine Candidate — MHRP and NIAID researchers developed a new HIV
vaccine, specific to the strain of HIV circulating in Southeast Asia that is expressed in a modified smallpox virus vector
vaccine, specific to the strain of HIV circulating in Southeast Asia that is
expressed in a modified smallpox virus
vector (MVA).
Recombinant:
Vaccine manufactured through gene cloning (plasmid
expressed) or by recombining selected DNA from a pathogenic organism with DNA from another virus (viral
vectored), leading to the expression, following inoculation, of only essential antigens required to immunize.